Tuesday, January 28, 2014

International Stem Cell Corp. (ISCO): Changing the Field of Regenerative Medicine with Unique, Self-Sustaining Business Model

International Stem Cell is focused on exploring and advancing the therapeutic applications of human stem cells as well as the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells, parthenogenetic stem cells, created from unfertilized human eggs, and has established a strong patent portfolio offering clean intellectual property and freedom to operate.

Utilizing a strategy much different than the majority of other players in the biotech space, International Stem Cell generates revenues from its individual subsidiary business units that sell products developed from scientific discoveries made by International Stem Cell. Not only is this model self-sustaining with revenues used to support scientific research and development, it also provides practical, short-term applications of the core technologies.

The Lifeline Cell Technology (LCT) and Lifeline Skin Care (LSC) commercial businesses provide the foundation for International Stem Cell’s short-term application. For the six-months ended June 30, 2013, International Stem Cell reported revenues of $2.74 million, compared to revenues of $2.13 million for the prior year period. LCT contributed $1.38 million, up 30 percent year-over-year, while LSC contributed $1.36 million, an increase of 27 percent from the same period in 2012.

Therapeutic programs, including those addressing Parkinson’s disease, metabolic liver disease and corneal blindness, make up International Stem Cell’s medium-term applications. In regards to its Parkinson’s disease program, International Stem Cell has carried out several stem cell-based experiments and recently concluded its first pilot primate study with favorable results. In mid-2104, the company plans to submit to the U.S. FDA an investigational new drug (IND) application, and recently engaged Duke University as a partner to carry out the phase I clinical study of Parkinson’s disease in human subjects.

International Stem Cell’s long-term strategy is focused on therapeutic products, licensing revenue and the company’s stem cell bank, UniStemCell, the life science industry’s first collection of non-embryonic histocompatible human stem cells available for research and commercial use.

Each aspect of International Stem Cell’s business model is centered on the company’s proprietary stem cell technology. The company’s stem cells present superior immune matching capabilities and can be used in millions of people, regardless of their sex or racial background, with minimized expectation of immune rejection following transplantation.

For more information visit www.internationalstemcellcorp.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: